Endoscopy technology developer Karl Storz Endoscopy America Inc. has received an innovative technology designation from healthcare improvement company Vizient Inc. Blue Light Cystoscopy with Cysview provides a solution for enhanced detection and management of non-muscle invasive bladder cancer, as illustrated in this image. Courtesy of Karl Storz. The designation was based on reviews by hospital experts for the company’s D-Light C Photodynamic Diagnostic (PDD) system in conjunction with Cysview, an optical imaging agent distributed in the U.S. by Photocure Inc. The combined system is used to enhance the detection and management of non-muscle invasive bladder cancer (NMIBC) in patients with known or suspected bladder cancer, based on prior cystoscopy. “Due to the number of products and services being released and marketed as innovative, member hospitals truly value the peer-review system in place at Vizient to help them identify products worth further evaluation at their own facilities,” said Debbie Archer, director of procurement and leader of Vizient’s Innovative Technology program for suppliers. “After a review of Blue Light Cystoscopy with Cysview, Vizient’s member council agreed this solution offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology designation.” Vizient represents the combined strengths of the organizations formerly known as VHA Inc., the University HealthSystem Consortium, Novation and MedAssets’ Spend and Clinical Resource Management. “Use of the Karl Storz D-Light C PDD system for BLCC procedures gives vital new capabilities to physicians,” said John Martineau, director of marketing urology for Karl Storz. “Used as an adjunct to white-light cystoscopy, BLCC is the only FDA-approved technology that is shown to improve detection of bladder cancer tumors, hence leading to improved and more comprehensive tumor resection.” Karl Storz Endoscopy is a developer of reusable endoscope technology.